Re Agreement

ReNeuron Group plc
30 November 2006

ReNeuron and CellSeed announce collaboration using ReNcell(TM) liver cell lines

Guildford, UK, 30 November 2006:  ReNeuron Group plc (LSE: RENE.L) and CellSeed
Inc., a privately owned tissue engineering company based in Tokyo, Japan, today
announce the signing of a collaboration agreement to develop novel, patented
liver cell culture systems for drug safety screening in the pharmaceutical
industry.

The development work, to be conducted in CellSeed's laboratories in Tokyo, will
establish protocols for efficiently developing ReNeuron's patented 
ReNcell(TM) HEP hepatocyte cell lines in combination with CellSeed's UpCell and 
HydroCell temperature-sensitive polymer products for 3-dimensional functional 
liver tissue.  3-D liver culture systems represent the most effective way to 
assay for human liver toxicity of new drugs. The collaboration will enable the 
joint development of new, high-value, human cell-based drug discovery products 
for use in the pharmaceutical industry.  If the collaboration is successful, 
these products are expected to be launched in 2007.

ReNeuron's ReNcell(TM) HEP cell lines, developed with the Company's proprietary
c-mycER(TAM) cell expansion technology, express similar markers for drug
metabolism as those seen with primary adult hepatocytes. Unlike primary
hepatocytes, however, ReNcell(TM) HEP cells can be readily expanded to provide a
stable, plentiful and well-characterised source of liver cells for cell-based
toxicology screening applications.

Dr John Sinden, Chief Scientific Officer of ReNeuron, said:

'We very much look forward to working with CellSeed.  They have developed the
ideal complementary technology required to take our ReNcell(TM) HEP cell lines
into the engineered tissue field, in order to provide the next generation of
commercial drug discovery tools.'

Dr Yukio Hasegawa, President and CEO of CellSeed said:

'We are delighted to be working with a company as innovative as ReNeuron. The
combination of CellSeed's UpCell 3-dimensional cell-sheet engineering technology
with ReNeuron's cell expansion expertise provides the basis of a completely
novel drug screening system.'

Enquiries:

ReNeuron
Michael Hunt, Chief Executive Officer                    Tel: [phone]
John Sinden, Chief Scientific Officer

Financial Dynamics
David Yates                                              Tel: [phone]
Nicola Daley


Notes to Editors

About ReNeuron Group plc

ReNeuron is a leading, UK-based adult stem cell therapy business.  The Group is
applying its novel stem cell platform technologies in the development of
ground-breaking stem cell therapies to serve significant and unmet or poorly-met
clinical needs.

ReNeuron has used its c-mycER(TAM) technology to generate genetically stable
neural stem cell lines.  This technology platform has multi-national patent
protection and is fully regulated by means of a chemically-induced safety
switch.  Cell growth can therefore be completely arrested prior to in vivo
implantation.

The Group's lead stem cell therapy, ReN001 for chronic stroke disability, is in
late pre-clinical development.  The Company plans to file for approval to
commence a Phase I clinical study in stroke by the end of 2006, with the study
commencing as soon as possible thereafter.   There are an estimated 
50 million(1) stroke survivors worldwide, approximately half of which are left 
with permanent disabilities.  The healthcare costs of caring for these patients 
is estimated to amount to $45 billion(2) in the US alone.

ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcell(TM) range of cell lines for use in research and in drug
discovery applications in the pharmaceutical industry.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L,
and its warrants are traded under the symbol RENW.L.

Further information on ReNeuron and its products can be found at
www.reneuron.com.

(1). MOSES (Morbidity and mortality after stroke - Eprosartan vs nitrendipine for
     secondary prevention) study, Feb 2006
(2). American Heart Association, Reporting Standards for Carotid Artery
     Angioplasty and Stent Placement, (Stroke, 2004; 35:e112).


About CellSeed Inc.

CellSeed Inc. is a Japan-based biotechnology innovator committed to development
and commercialisation of highly differentiated tissue-engineered products for
patients that are not sufficiently served by current medical technologies.

CellSeed owns novel cell-sheet engineering technology developed by Professor
Okano at Tokyo Women's Medical University. The core technology is based on
grafting any kind of synthetic polymers to organic materials covalently at
nano-thickness level. When CellSeed's temperature-responsive polymers are
grafted to the cell culture surface, the recovery of intact cells retaining
important cell surface proteins becomes possible through temperature control.
This process avoids the use of potentially damaging enzymatic treatment such as
the use of trypsin when detaching cells from the cell culture surface.  Cells
cultured in this way can be collected in a form of contiguous cell-sheet rather
than as isolated cells. This tissue requires no suture when grafted to patients
and the cell-sheets can be piled together to create 3-dimensional tissue.

CellSeed's lead product is regenerated living cornea epithelium, targeting poor
epithelium recovery after corneal grafts and persistent epithelial defects.  An
IND for this product is being filed in Europe, with initiation of clinical
trials expected in 2007.

Cellseed is also applying its core technology beyond tissue-regeneration. The
Company is distributing its novel cell cultureware products, such as RepCell and
HydroCell, for the worldwide research market. The Company also recently launched
its Aqua Way series, a novel HPLC column which separates small molecules,
peptides and proteins using a temperature-controlled method.

Further information on CellSeed can be found at www.cellseed.com.


This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.


                      This information is provided by RNS
            The company news service from the London Stock Exchange